Statera BioPharma (FRA:7CB) NonCurrent Deferred Liabilities: €0.00 Mil (As of Sep. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7CB Statera BioPharma Inc FRA:7CB
20 GF Score
Price €2.61
View Full Analysis

What is Statera BioPharma NonCurrent Deferred Liabilities?

Statera BioPharma FRA:7CB 20 NonCurrent Deferred Liabilities is €0.00 Mil as of Sep. 2022. GuruFocus rates FRA:7CB with a GF Score™ of 20/100.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Statera BioPharma's non-current deferred liabilities for the quarter that ended in Sep. 2022 was €0.00 Mil.

Statera BioPharma NonCurrent Deferred Liabilities Related Terms

Statera BioPharma NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma NonCurrent Deferred Liabilities Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
NonCurrent Deferred Liabilities
0.00 0.00 0.00

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:7CB
20GF Score
Statera BioPharma Inc FRA:7CB
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of €0.00 Mil mean?
Statera BioPharma (FRA:7CB) has a NonCurrent Deferred Liabilities of €0.00 Mil as of Sep. 2022. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Statera BioPharma and its competitors.
Is Statera BioPharma's NonCurrent Deferred Liabilities too high?
Statera BioPharma's current NonCurrent Deferred Liabilities is €0.00 Mil. Overall, Statera BioPharma has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Statera BioPharma's NonCurrent Deferred Liabilities compare to NRBO and PALI?
Statera BioPharma's NonCurrent Deferred Liabilities of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Statera BioPharma and its competitors. Statera BioPharma's current NonCurrent Deferred Liabilities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (FRA:7CB) has a current NonCurrent Deferred Liabilities of €0.00 Mil. The current NonCurrent Deferred Liabilities is €0.00 Mil. Statera BioPharma's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Statera BioPharma (FRA:7CB), the current NonCurrent Deferred Liabilities is €0.00 Mil as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.
20GF Score

Get the complete analysis for FRA:7CB

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.61
Price